Nantahala Capital Management LLC Has $77,000 Stock Holdings in Lucid Diagnostics Inc. (NASDAQ:LUCD)

Nantahala Capital Management LLC cut its holdings in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) by 25.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 94,541 shares of the company’s stock after selling 31,821 shares during the quarter. Nantahala Capital Management LLC’s holdings in Lucid Diagnostics were worth $77,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. LPL Financial LLC boosted its position in Lucid Diagnostics by 29.1% during the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock worth $44,000 after buying an additional 12,035 shares during the period. Lido Advisors LLC boosted its position in Lucid Diagnostics by 40.0% during the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock worth $115,000 after buying an additional 40,000 shares during the period. Geode Capital Management LLC boosted its position in Lucid Diagnostics by 30.9% during the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock worth $229,000 after buying an additional 65,964 shares during the period. Finally, Sargent Investment Group LLC acquired a new stake in Lucid Diagnostics during the 4th quarter worth approximately $442,000. 74.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on LUCD. Ascendiant Capital Markets raised their price target on shares of Lucid Diagnostics from $7.00 to $7.50 and gave the stock a “buy” rating in a report on Monday, April 21st. BTIG Research set a $2.00 price target on shares of Lucid Diagnostics in a report on Tuesday, March 25th. Needham & Company LLC restated a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a report on Friday, April 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $2.00 price target on shares of Lucid Diagnostics in a report on Wednesday, March 26th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $3.50.

Lucid Diagnostics Price Performance

NASDAQ:LUCD opened at $1.33 on Monday. The company has a fifty day moving average of $1.40 and a 200-day moving average of $1.09. The firm has a market capitalization of $140.16 million, a P/E ratio of -1.17 and a beta of 1.26. Lucid Diagnostics Inc. has a twelve month low of $0.68 and a twelve month high of $1.80.

Lucid Diagnostics Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.